Antiemetics

Publication Date: July 13, 2020

Key Points

  • The development of increasingly effective antiemetic regimens over the last quarter century has greatly reduced the incidence of nausea and vomiting due to chemotherapy.
  • The recommended approach to preventing nausea and vomiting varies by the emetic risk of the treatment regimen.
  • Adherence to antiemetic guidelines has been linked with improved control of nausea and vomiting.
  • This update of the 2017 guideline adds guidance on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs).

Treatme...

...lt Patients...

...ult patients, the addition of a checkpo...

...etic-Risk Antineoplastic Age...

...t patients treated with cisplatin and o...

...ts treated with an anthracycline combined with...

...rate-Emetic-Risk Antineoplastic Agent...

...t patients treated with carboplatin area...

...treated with moderate-emetic-risk antineoplast...

...ients treated with cyclophosphamide, doxorubic...

...isk Antineoplastic Agents...

...patients treated with low-emetic-ris...

...l Emetic Risk Antineoplastic Agen...

...patients treated with minimal emetic ris...

...eoplastic Combination...

...dult patients treated with antineop...

...ctive Drugs

...am is a useful adjunct to antiemet...

...annabinoi...

...remains insufficient for a recommenda...

...ementary and Alternative Therapies...

...e remains insufficient for a recommend...

...therapy With Stem-Cell or Bone Marrow Transpla...

...dult patients treated with high-dos...

...New) A four-drug combination of an NK1 receptor...

...iday Antineoplastic Therapy

...s treated with multiday antineoplastic agents...

...reated with 4- or 5-day cisplatin regimens...

...akthrough Nausea and Vomiting...

...tients with breakthrough nausea or vomiting, cli...

...patients who experience nausea or vomiting despi...

...nol and nabilone ( IC , I , M )6539...

...erwise ( IC , L , M )653...

...patory Nausea and Vomitin...

...patients should receive the most active ant...

...ic Risk Radiation Therapy...

...dult patients treated with high-emetic-risk r...

...ate Emetic Risk Radiation Therapy...

...lt patients treated with moderate-emetic-risk r...

...c Risk Radiation Therapy...

...lt patients treated with radiation therapy t...

...imal Emetic Risk Radiation Therapy...

...reated with minimal emetic risk radiation t...

...oncurrent Radiation and Antineoplastic Ag...

...tients treated with concurrent radiatio...


...iatric Patie...

...Emetic Risk Antineoplastic Agent...

...pdated) Pediatric patients treated with...

...ric patients treated with high-emetic-risk anti...

...dated) Pediatric patients treated with high-...

...te Emetic Risk Antineoplastic Agents...

...iatric patients treated with moderat...

...atric patients treated with moderate...

...c Risk Antineoplastic Agents...

...iatric patients treated with low-em...

Minimal Emetic Risk Antineoplastic Agen...

...atric patients treated with minimal emeti...


...metic Risk of Single Intravenous Antineoplastic...


...Emetic Risk of Single Oral Antineopla...


...metic Dosing for Adults by Chemotherapy...


...e 4. Emetic Risk in Adults by Site...


...able 5. Antiemetic Administration in Adults by R...